The nicotinic acetylcholine receptor (nAChR) and the acetylcholine binding protein (AChBP) are pentameric oligomers in which binding sites for nicotinic agonists and competitive antagonists are found at selected subunit interfaces. The nAChR spontaneously exists in multiple conformations associated with its activation and desensitization steps, and conformations are selectively stabilized by binding of agonists and antagonists. In the nAChR, agonist binding and the associated conformational changes accompanying activation and desensitization are cooperative. AChBP, which lacks the transmembrane spanning and cytoplasmic domains, serves as a homology model of the extracellular domain of the nAChRs. We identified unique cooperative binding behavior of a number of 4,6-disubstituted 2-aminopyrimidines to Lymnaea AChBP, with different molecular variants exhibiting positive, n H > 1.0, and negative cooperativity, n H < 1.0. Therefore, for a distinctive set of ligands, the extracellular domain of a nAChR surrogate suffices to accommodate cooperative interactions. X-ray crystal structures of AChBP complexes with examples of each allowed the identification of structural features in the ligands that confer differences in cooperative behavior. Both sets of molecules bind at the agonist-antagonist site, as expected from their competition with epibatidine. An analysis of AChBP quaternary structure shows that cooperative ligand binding is associated with a blooming or flare conformation, a structural change not observed with the classical, noncooperative, nicotinic ligands. Positively and negatively cooperative ligands exhibited unique features in the detailed binding determinants and poses of the complexes.
allostery | crystallography | nicotinic receptor N icotinic acetylcholine receptors (nAChRs) function as allosteric pentamers of identical or homologous transmembrane spanning subunits. Ligand binding at two or more of the five intersubunit sites, located radially in the extracellular domain, drives a conformational change that results in the opening of a centrosymmetric transmembrane channel, internally constructed among the five subunits (SI Appendix, Fig. S2A ) (1) (2) (3) (4) . Up to five potential agonist-competitive antagonist sites on the pentamer are found at the outer perimeter of the subunit interfaces. Amino acid side-chain determinants on both subunit interfaces dictate selectivity among the many subtypes of nAChRs. The interconversion between resting, active, and desensitized states occurs in the absence of ligands, and partial occupation of the binding sites suffices for agonist activation of the receptor and its antagonism (5-7). Cooperativity of agonist association and its coupling to channel gating likely play important roles in the dynamics of nicotinic responses and in sharpening the concentration and temporal windows for activation.
As revealed in functional studies, most nAChRs are heterooligomeric, where the sites of ligand occupation are not identical (1) (2) (3) (4) . This arrangement arises when a common α-subunit pairs with one or more nonidentical subunit partners, termed non-α-subunits (7, 8) . Nonidentity of the subunit interface complementary to the α-subunit may also give rise to heterogeneity in binding constants typically seen for antagonists and mask partially the degree of agonist cooperativity. An exception to this is the α7-neuronal nAChR composed of five identical subunits and exhibiting a high degree of cooperativity for agonist activation (9). Recently, sequence alignments identified genes coding for pentameric ligand-gated ion channels in prokaryotes led to the resolution of the first structure by X-ray crystallography on 3D crystals of a pentameric receptor protein from Erminia chrysanthemi (ELIC) (10) and Gloeobacter violaceus (GLIC) (11, 12) and provided high-resolution structures of the two end point states of the cooperative gating mechanism in the same pentameric ligand-gated ion channel (GLIC) (13). Recently, the first structure of a eukaryotic member of the family, the anionic glutamate receptor from Caenorhabditis elegans (GluCl), was solved at atomic resolution (14), revealing remarkable identity of 3D structure with GLIC.
The acetylcholine binding protein (AChBP) was characterized from mollusks (15-17) and consists of only a homologous extracellular domain of the nAChR. Assembled as a homomeric pentamer, AChBP exhibits a similar profile of ligand selectivity toward the classical nicotinic agonists and antagonists of quaternary amine, tertiary and secondary amine (alkaloid), imine, and peptide origin that bind nicotinic receptors (18) (19) (20) (21) (22) (23) (24) (25) . If looked at solely on the basis of ligand-binding capacities, AChBP could be considered as a distinct subtype of nAChR. Although its Significance Heretofore, ligand recognition at each subunit interface of the acetylcholine binding protein (AChBP) has been found to be independent of the other interfaces, representing a disconnection between the properties of the AChBP and the full receptor that it is intended to model. These results comprise the first examples of cooperative binding with the extracellular domain, providing insights into the structural basis for interactions between subunits. Within a single series of congeneric molecules, both positively and negatively cooperative behaviors toward AChBP are manifest. Hence, a distinct mode of binding to the agonist-competitive antagonist site is established in the AChBP protein.
homomeric composition and ligand selectivity best resemble the α7-subtype of nAChR, when the concentration dependence of ligand occupation has been examined, no evidence of cooperativity emerged (21). Accordingly the cooperative behavior for both activation and desensitization of receptors, seen for the classical nicotinic agonists with nAChRs, might arise from a cooperative torsional motion driven by the transmembrane spanning domain of the receptor (26).
We demonstrate here a set of ligands that bind to the AChBP in a cooperative fashion, whereby binding to a single subunit affects the binding energy at identical interfaces in the pentamer. Hence, interactions within the extracellular domain of this family of homologous pentameric proteins establish a circumferential linkage between subunit interfaces which results in cooperative behavior.
Results

Association of Substituted 2-Aminopyrimidines with AChBP Reveals
Positive and Negative Cooperativity. After preliminary assessment of other scaffolds, we focused our attention on 4,6-disubstituted 2-aminopyrimidines as being representative of drug-like molecules having a propensity to associate with neurological signaling receptors. These compounds showed selectivity for binding to Lymnaea stagnalis (Ls)-AChBP when characterized in a radioligand competition assay. The compounds could be divided in three groups of binding profiles based on Hill coefficients: ligands with n H < 1, n H ∼ 1, and n H >1 (Fig. 1 ). Nicotine competition with epibatidine served as our positive control and is an example of a noncooperative ligand for AChBP with n H = 1. If the binding of ligand at one site increases the affinity for ligand at a corresponding homologous sites on the pentamer, the ligand exhibits positive cooperativity (n H > 1) with AChBP. Conversely, if the binding of ligand at one site diminishes the affinity for ligand at another site, the protein exhibits negative cooperativity or site heterogeneity, n H < 1. Hence, partial occupation of sites in the pentamer diminishes allosterically with occupation of the remaining sites.
Overall, a broad range of affinities are revealed in this series of congeneric compounds with apparent K d values of 0.2 nM to >10 μM (Table 1 and SI Appendix, Table S4 ). Many compounds from the series showed Hill slope values close to one (Table 1 ; 28 and 37). However, compounds with large Hill coefficients were identified and were found to exhibit lower, but still respectable, affinities ( Fig. 1; 1 and 15) . In contrast, some ligands with shallow titration curves bound with exceptionally high affinity ( Fig. 1 ; 30 and 32). There was significant tolerance to substitution at position 4 of the pyrimidine ring, accepting lipophilic alkyl (Table 1; 12-15) and aryl (Table 1 ; 28-30), as well as more polar groups (Table 1 ; 27 and 35). These substituents strongly influence the range of ligand K d and Hill coefficients. A few heterocyclic aromatic rings substituted at 6-position were tested (Table 1 ; 9-10, SI Appendix, Table S4 ; 11), but no aryl group was found to give superior activity compared with the substituted phenyl ring.
Crystal Structures of Ls-AChBP with Substituted 2-Aminopyrimidines Shows Distinctive Tertiary Structural Changes at the Binding Interface.
To gain structural insight, crystallization of several complexes was attempted. Crystal structures with Ls-AChBP in complex with ligands showing negative (32, Fig. 2 A and B; 33, Fig. 2C ; chains A and B) and positive (15, Fig. 2D ; chains D and E) cooperativity were refined to 3.0, 2.1, and 2.7 Å, respectively. For statistics on data collections, see SI Appendix. The Ls-AChBP complex with bound cooperative ligands reflected full occupation of the pentamer and a well-resolved electron density of all 10 subunits (Fig. 2 A and B) . Ligand 15 has a clear electron density for the biaryl ring of the molecule, but a poor density of the alkyl chain possibly arising from multiple flexible conformations of the C loop. Several residues in F the loop (T155-E163) gave unresolved electron densities and were consequently excluded from the models. Additionally, in complex with ligand 15, residues 185-189 in the C loop encompassing the vicinal Cys-Cys bond were not seen in 9 of 10 subunits of the dimer of pentamers.
The structure of Ls-AChBP in complex with 33 superimposed on 32 with an RMS deviation of 0.38 Å for 1,212 Cα atoms ( Fig. 2C ) and on 15 with an RMS deviation of 0.34 Å for 1,132 Cα atoms (Fig. 2D) . Binding orientations show a high degree of similarity at all five binding sites in each pentamer and a similar orientation of the ligands. All three compounds bind underneath a closed C loop at the interface between two subunits. Loop closure in the presence of bound ligands, as measured from the backbone carbonyl of W143 in the A loop to the γ-sulfur atom of the first vicinal Cys disulfide-linked residue in the C loop (C187 in Ls-AChBP), is 8.4 Å for 32 and 33 structures and 8.2 Å for 15. The ligands contact amino acids from both the principal face with residues from loops A (Y89), B (W143), and C (Y185 and Y192), and complementary face (loops D, W53; E, L112 and M114; and F, Y164). Parallel displaced π-stacking interactions with W143 are present in all structures. Importantly, the pyrimidine ring of 15, the ligand showing positive cooperativity, rotates by ∼26-36°compared with 32 and 33 showing negative cooperativity (SI Appendix, Fig. S5 ). The ring rotation results in its parallel alignment with Y192 side chain (2.9 Å and greater). The only potentially protonable nitrogen in the ligands at physiological pH is in the pyrimidine ring at the position N1 (pK a ∼ 6.7-6.8; computed by Marvin Sketch 5.12.3). It resides within hydrogen bonding distance of the carbonyl backbone oxygen of W143 (2.7-2.9 Å) and as close as 3.8-3.9 Å to the W143 side-chain aromatic ring. Other interactions in the complexes come from polar contacts formed by ligands N2 atoms with the hydroxyl group of the Y89 side chain from the B-loop (2.9 Å in 32 and 33; 2.7 Å in 15) and carbonyl oxygen of S142 (2.6-2.8) Å for all three ligands. Morpholine (32) or 4-methyl-piperidine (33) substituents appear to associate with Y89 and Y185. Nitrogen atoms of these rings are positioned to stack with all seven atoms of the Y185 ring with distances ranging between 3.6 and 4.3 Å. Interactions of these substituents on the complementary subunit face are predominantly hydrophobic. The altered position of the indole of W53 in 32 and 33, compared with 15, is associated with a change in side-chain orientation of neighboring residues M114 and Q55. Phenyl rings substituted at the pyrimidine 6-position interact mainly with W143, Y192, and C188. Additionally, fluorines in trifluoromethyl substituent are in the vicinity of the T144 side chain and interact with multiple loop F residues, including L112 and M114, as well as neighboring water molecules, with interaction extending to M114 and R104 side chains. The flexible aliphatic chain of 15 at the 4 position in the pyrimidine does not yield discernable electron densities except for chain D. Lack of density likely reflects multiple conformations of the flexible C loop not constrained by the symmetry related molecule in the crystal structure. Rotation of the pyrimidine ring and presence of the alkyl chain in 15 brings the ligand in close contact with Y185 side chain (∼3.0 Å to N4 of the ligand) and causes the tyrosine ring to rotate toward the gorge interface presumably to avoid a clash with the alkyl chain of the ligand. Also, the indole of W53 on the complementary face rotates toward the subunit interface and is in contact with ligand N4 (3.5 Å). The phenyl ring in ligand 15 has a similar position as the aromatic ring in complexes 32 or 33, but its contacts are altered by methoxy-substituent interacting with T144 and with L102, L112, and M114 in the complementary face. Major differences for 15, compared with complexes of ligands showing negative cooperativity, are seen in Y185, Y164, M114, and W53 side-chain conformations.
The interactions of 32/33 are compared with nicotine the in Ls-AChBP binding pocket [Protein Data Bank (PDB) ID code 1UW6] (18) in Fig. 3A . The pyrrolidine ring in nicotine only partially overlaps with pyrimidine ring of cooperative ligands, and nitrogens of these substituents are well aligned. In contrast to nicotine, the side chain of Y89 shifts to bring its hydroxyl group in hydrogen bonding distance of the pyrimidine nitrogens in the 32, 33, and 15 crystal structures. Striking differences in side-chain positions in nicotine complex compared with 32 and 33 are seen on the complementary face of the binding site that forms interactions through residues that are only partially conserved in AChBPs from different species. To accommodate the morpholine or methylpiperidine substituents in the 32/33 complex, the indole side chain in W53 changes its rotameric position. As a consequence, M114 is brought in contact with the 6-substituted trifluoromethyl phenyl group of the ligand. The position of the 32/33 phenyl ring is similar to the pyridine ring in nicotine. The trifluoromethyl group forces L112 to change its rotameric position. The presence of fluorines, however, affords additional hydrophobic stabilization with multiple residues on complementary subunit.
Compared with the nicotine-AChBP complex, loop C in ligand 15 (chain D) shows significant variation, reflected in the Y185 side-chain conformation (Fig. 3B) . Residues W53 and M114 in the 32/33 complexes, that represent most significant departures from nicotine, in the 15 X-ray structure have orientations similar to those in the nicotine complex. However, the indole ring of W53 side chain has more extensive contacts with the ligand 15 than with nicotine, through its substituent at the position 4 in the pyrimidine ring. To avoid steric occlusion with Y185 in the complex, the rotational state of Y164 on complementary face changes as well.
Quaternary Structural Changes of Ls-AChBP. Superimposing LsAChBP in the Apo form with the complexes of substituted 2-aminopyrimidines showing cooperativity (ligands 15, 32, and 33) also revealed a major change in quaternary structure (Fig.  4A) . Distances between Cα for T13 in the apical α-helices of 
uoromethyl)phenyl 0.11 ± 0.03 1.3 ± 0.4 diametrically opposed subunits showed 7 Å greater transsubunit spans than for the Apo reference structures or the nicotine complex. By superimposing a single chain in each pentamer (Fig.  4B ), differences in tertiary structure could be observed for six regions (RMSD ∼ 5 or greater; Swiss-PdbViewer): residues 8-14 (N-terminal α-helix) and loops 22-24, 43-44 (loop connecting β1 and β2), 61-69 (η1 and its continuation), 156-162 (region in β8 N-terminal to loop F), and 182-185 (part of β9 and loop C). Based on a similar analysis for nicotine and carbamylcholine Ls-AChBP crystal structures (SI Appendix, Fig. S2 ), differences observed for four regions appeared to be unique for cooperative ligand complexes (regions 8-14, 22-24, 42-43, and 61-69). To quantify observed variations, two types of calculations were performed using 1UX2 as a reference structure (for detailed description of calculations, see SI Appendix). Differences in distances between every α-carbon (Cα) of diametrically opposed subunits were calculated relative to the reference structure (Fig. 4C) . Additionally, differences in dihedral angles for every Cα residue were calculated (using three reference points) relative the reference structure (Fig. 4D ).
Values were compared with those obtained for the nicotine complex and the open and closed states of prokaryotic GLIC protein (13). For the α-carbon distances (Fig. 4C ), significant differences compared with nicotine complex were observed for residues 1-120, with the largest differences emerging in the N-terminal helix. Interestingly, these differences showed similar patterns in linear sequence to those observed for GLIC (13) and are described as a blooming motion of the protein extracellular domain. Region 155-162 in complex 15 shows a significant distance reduction compared with nicotine. This region is a highly flexible segment of the protein, as is the case for complexes 32 and 33, where this region is omitted due to limiting densities in the crystal structure. Although short sequence regions in the crystal with positively cooperative ligand 15 diverge from crystals of 32/33 with negative cooperativity (e.g., residues 182-189), owing to differences between ligands 32 and 33 themselves, interpretation of the fine structural differences between 15 and 32 and 33 will require additional study. Based on the rearrangements observed at the interface of the orthosteric agonist/antagonist pocket (SI Appendix, Fig. S3 ) the greatest deviations from nicotine (up to ∼4 Å) are evident for Y185 and C187-8 in the crystal structure of the 32 and 33 complexes.
Relative differences of dihedral angles show small torsional or twist motions seen for residues 1-23 with as much as a 5°shift for R11. Also, residues 157-160 exhibit a similar tendency with changes up to 8°. Data for 32 and 33 overlay very well and do not differ much from 15 across the entire sequence, especially for the abovementioned regions with greatest torsional motions that are not observed for nicotine. However, the patterns of dihedral angle changes are far smaller than seen in the GLIC structure and AChR models (13, 26, 27 ).
An alternative presentation of the data is shown in SI Appendix, Fig. S2 , and all values were projected onto a centrosymmetric axis in the pentamer, and they reflect relative distances from a reference point at the transmembrane region interface. The blooming amplitude develops from cytoplasmic toward the extracellular, apical region, resulting in increased intersubunit distances between diametrically opposed, nonadjacent subunits. Accordingly, the blooming quaternary structure is evident for all three members of the 2-aminopyrimidine series and emphasizes the importance of the conformational differences in quaternary structure associated with the state changes. These sequence patterns of quaternary rearrangements reflected in distances between diametric subunits are in close correspondence in residue positions with those found in the open and closed channel forms of GLIC (13).
Discussion
Our studies establish a previously unknown level of conformational communication between AChBP subunits accompanying ligand binding. We report a series of selective AChBP ligands exhibiting negative, as well as positive cooperativity, a type of allosteric behavior in which binding interactions in an oligomeric protein take place between distant subunit interfaces. Selected ligands showing marked differences in cooperativity were used to obtain three atomic resolution, X-ray crystal structures of ligands with different Hill slope values in their complexes with Ls-AChBP. The lower affinity ligands showing positive cooperativity, along with the high affinity of the negatively cooperative ligands, serve to achieve full occupation of ligand in the crystal structures.
These cooperative interactions occur in the absence of the transmembrane, channel gating domain required of the nAChR to elicit subunit interactions and cooperativity. Rather cooperativity in AChBP is confined to the extracellular domain of the nAChR reference structure and is mediated circumferentially around the cylindrical pentamer.
The differences in side-chain positions at the subunit interface (W53, Y164, and Y185) that distinguish between positively and negatively cooperative ligands also diverge from the nicotine sidechain positions. Nicotine also adds Y89 to the perturbed side chains. Changes in quaternary structure noted in reference to the gating transition of prokaryotic GLIC, as blooming (13, 27), are not seen for nicotine and carbamylcholine, where the Apo form of the receptor is used as a reference state. However, it should be recognized that the apo-receptor contains Hepes buffer occupying the reference site (16). Hence, at this stage, an nAChBP unoccupied by a ligand is not available in a crystallized form.
Nevertheless, we should ask what distinguishes the substituted 2-aminopyrimidines from the conventional ligands hitherto fore characterized. They may fit into three categories: (i) quaternary amines stabilized by a cation-π interaction between the cation and a nest of surrounding aromatic side chains. Such interactions are evident in the crystal structures of acetylcholine, carbamylcholine, and other quaternary complexes (16, 18), and the energetics have been established through mutagenesis studies modifying the polarizability, and electronegativity of the aromatic side chains in the binding pocket (28, 29); (ii) secondary and tertiary amines (19-21) and imines (21), which, when in a protonated state, hydrogen bond to the backbone carbonyl of W143. The protonated dihydropyridine-bound state for the benzylidene anabaseines has been demonstrated by difference spectroscopy (30); and (iii) peptides, such as the α-conotoxins and α-neurotoxins, stabilized by multiple interactions on the C loop and interfacial residues on both the principal and complementary faces (31-34). The binding interactions of the 2-aminopyrimidines do not appear to follow the above patterns and therefore these structures constitute a distinct fourth group of ligands. The nitrogens in the 2-aminopyrimidine ring are not very basic, suggesting a far higher energy requirement for the ligand to bind in a protonated state than that found for secondary and tertiary amines and the imines. Hence, the 2-aminopyrimidines may be considered as electron-rich ring systems capable of ring stacking with the side chains of Y192 and W143. The pyrimidine ring nitrogens are not as exposed as the bicyclic ring in epibatidine and the pyrrolidine nitrogen in nicotine affording a proper directionality for hydrogen bonding. Thus, the global conformational changes primarily manifested by blooming appear characteristic of the substituted 2-aminopyrimidines and are not seen with carbamylcholine and nicotine (Fig. 4 and SI Appendix, Fig. S2 ). To date, a clear state change has only been documented for the substituted 2-aminopyrimidines.
The changes in AChBP quaternary structure add another dimension to considering subunit interactions. The blooming and torsional conformational changes noted with AChBP show analogies with those observed in GLIC (13, 27) in relation with correspondences of protein sequence (Fig. 4 A-C and SI Appendix, Fig. S2 ). The amino terminal helix, regions between residues 58 and 70 and between 106 and 110, all show increased distances between diametrically opposed subunits. The sharper negative peaks around residues 156 and 185 likely involve local perturbations of the C and F loops proximal to the ligand binding site resulting in local compaction of the structure, measured in Cα distances. The comparison of the dihedral bond angles should reflect a torsional or twist motion as seen between the two states of GLIC (13, 27). Changes in dihedral angle positions are small (SI Appendix, Fig. S2C ), but involve the same set of residues. Hence, when the binding of the 2-aminopyrimidines are compared with the pH-dependent conformations of GLIC, the dominant PHARMACOLOGY common change is found with the Cα distances between diametric subunits (blooming) (SI Appendix, Fig. S2B ) rather than the dihedral angles for torsional movement (twist) (SI Appendix, Fig. S2C ). The interfacial binding sites residing under the C loop of AChBP and the nAChR appear surprisingly accommodating for the binding of ligands of a different structure. For example, Stornaiaolo and colleagues reported on large planar, aromatic molecules binding under the C loop in a stacked sandwich fashion and extending the C loop (35).
The cooperative ligands binding to AChBP add a new dimension to ligands interaction with the extracellular domain of the pentameric ligand-gated ion channels. We are currently examining the structural determinants of selectivity of this ligand family with other AChBP's and the homomeric α7 nAChR. With homomeric nAChRs, selectivity for the primary agonist could be altered through partial site occupation by the 2-aminopyrimidines showing negative cooperativity. In the case of the predominant heteromeric receptors where the binding interfaces will differ, such ligands may possibly serve as positive or negative allosteric modulators at sites distinct from those occupied by agonist and competitive antagonist (36). Such appears to be the case for the benzodiazepines (36, 37) and other sedative agents (38) that act in this manner with the GABA receptor (39, 40). Accordingly, new dimensions for achieving pharmacologic selectivity for particular nAChR subtypes may result with the cooperative nAChR ligands possessing electron-rich substituted 2-aminopyrimidines.
Materials and Methods
Synthetic schemes and procedures are described in SI Appendix. Ls-AChBP was expressed and purified as previously described (30). A full description of protocols, screening methods (17) and crystallization details are provided in SI Appendix.
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General
Reagents and solvents were purchased from commercial sources and used without further purification. Unless otherwise stated, the reactions were performed under ambient conditions without attempts to exclude air or moisture other than capping the reaction vessels. NMR spectra were obtained on Brüker AMX-400 and Brüker Avance III 600 MHz instruments and referenced to the signals of residual 1protium in the NMR solvent. Splitting patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), pentet (p), doublet of doublets (dd), doublet of doublet of doublets (ddd), doublet of triplets (dt), triplet of doublets (td) and broad (b); the value of chemical shifts () are given in ppm and coupling constants (J) in hertz (Hz). Routine MS spectra were acquired in the positive ion mode using Agilent G2446A Lc/MSD Trap XCT coupled to an Agilent 1100 HPLC. Representative compounds were characterized by high-resolution mass spectrometry (HR-MS) by using an Agilent 6230 ESI-TOFMS. Analytical and preparative TLC was performed on aluminum-backed plates (EMD Chemicals, San Diego, CA) and visualized by exposure to UV light.
Synthetic procedures.
A straightforward synthetic pathway allowed access to multiple 2-aminopyrimidine analogs varying in substitution at positions 4 and 6 in the pyrimidine ring (Scheme S1). Commercially available 2-amino-4,6-dichloropyrimidine A was reacted with appropriate amines to afford intermediates B1-B24. In the subsequent step, compounds B were subjected to a coupling reaction with various boronic acids using tetrakis(triphenylphosphine)palladium(0) as a catalyst to give products 1-38 in good to excellent yields. If tertbutyloxycarbonyl (boc) protected the amine functional group in the described approach, free amines were generated by subsequent acidic cleavage with 10% trifluoroacetic acid solution in dichloromethane. This synthetic route enabled us to synthesize approximately 40 analogs of the lead with separate modifications at the 4 and 6 positions. Scheme S1. Synthetic pathway leading to 4,6-substituted 2-aminopyrimidines 1-38.
General procedure for synthesis of 4-chloro-6-aminopyrimidin-2-amines B1-B24.
An appropriate amine (2.20 mmol) was added to a solution of 4,6-dichloropyrimidin-2-amine (0.328 g, 2.00 mmol) and N,N-diisopropylethylamine (0.383 mL, 2.20 mmol) in DMF (3 mL) and the solution was stirred at 80 ºC for 2-6 hours (reaction monitored by TLC). The solvents were removed under reduced pressure, brine was added and the mixture was extracted with ethyl acetate (3 x 20 mL). The organic layers were washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated on a rotary evaporator, and the title compound was isolated by column chromatography on silica gel or by crystallization. General procedure for synthesis of 6-aryl-2,4-diaminopyrimidine 1-38. Appropriate bornonic acid (0.60 mmol) was added to a solution of appropriate chloropyrimidine (0.50 mmol) in toluene/ethanol (1:1, 4 mL). Sodium carbonate decahydrate (0.286 g, 1.0 mmol) was added following the addition of tetrakis(triphenylphosphine)palladium(0) (57.8 mg, 0.050 mmol). The resulting mixture was stirred in a capped glass vial at 95 C for 2-4 h. After cooling the mixture to room temperature, water was added and the mixture was extracted with ethyl acetate (3 x 20 mL). The organic layers were washed with brine, dried over anhydrous magnesium sulphate, and filtered. The filtrate was concentrated under reduced pressure and the crude product was purified by column chromatography on silica gel. Boc-protected pyrimidines (0.05 mmol) was dissolved in 10% TFA/DCM (1 mL) and the mixture was left for 1 hour at room temperature. The solvents were removed and the deprotected product was used without further purification. 
tert-Butyl
5-(2-amino-6-chloropyrimidin-4-ylamino)pentylcarbamate (B-5).
Purification: column chromatography on silica gel using hexane/ethyl acetate (4:1) and ethyl acetate/methanol (10:1) as the eluent. Colorless oil, 0.664 g, 99% yield. 1 3-(2-amino-6-chloropyrimidin-4-ylamino)propylcarbamate (B-7) . Purification: column chromatography on silica gel using hexane/ethyl acetate (4:1) and ethyl acetate/methanol (10:1) as the eluent. Yellow oil, 0.640 g, 99% yield. 1 -6-chloropyrimidin-4-ylamino)butanoic acid (B-8) . Purification: column chromatography on silica gel using ethyl acetate/methanol (10:1 and 7:1) as the eluent. White solid, 0.150 g, 34% yield. column chromatography on silica gel using hexane/ethyl acetate (2:1) as the eluent. White solid, 0.338 g, 72% yield.
tert-Butyl
4-(2-Amino
(s, 1 H), 7.27 (m, 1 H), 7.37 (d, J = 7.9 Hz, 1 H), 7.63 (td, J = 7.5, 1. 
4-Chloro-6-(4-methylpiperidin-1-yl)pyrimidin-2-amine (B-17).
Purification: column chromatography on silica gel using hexane/ethyl acetate (3:1 and 1:1) as the eluent. White solid, 0.407 g, 90% yield. Fluoro-4-(trifluoromethyl)phenyl)-N 4 -heptylpyrimidine-2,4-diamine (6). Synthesized using B-3 as the starting material. Purification: column chromatography on silica gel using hexane/ethyl acetate (6:1) as the eluent. Yellow oil, 0.135 g, 73% yield. -6-(4-(trifluoromethyl)phenyl)pyrimidin-4-ylamino) 13 Figure S1 . Examples of and 13 C (APT mode) NMR spectra. -6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine (32 Methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine (KK-33) 
4-Chloro-6-(4-(2-morpholinoethyl)piperazin-1-yl)pyrimidin-2-amine (B-19
5.89 (s, 1 H), 6.74 (s, 1 H), 7.43 (m, 1 H), 7.99 (s, 1 H). 13 C NMR (150 MHz, CDClH), 3.08 (m, 2 H), 3.28 (bs, 2 H), 5.09 (bs, 2 H), 6.13 (s, 1 H), 7.64 (m, 2 H), 7.96 (m, 2
4-(2-Amino
6-(4-Methoxyphenyl)-N
4-Morpholino
4-(4-
Protein Production and Purification.
The Ls-AChBP was expressed and purified as previously reported (1, 2) . Briefly, AChBP was expressed with an amino-terminal FLAG epitope tag and secreted from stably transfected HEK293S cells lacking the Nacetylglucosaminyltransferase I (GnTI−) gene. The protein was purified using FLAG-antibody resin and eluted with FLAG peptide (Sigma) and was further characterized by size-exclusion chromatography [Superose 6 10/300 GL column (GE Healthcare) in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.02% NaN 3 ]. Purified AChBP pentamers were then concentrated in a YM50 Centricon ultrafiltration unit (Millipore) removing monomeric subunits and trace contaminants. Protein concentrations were determined by UV absorbance at 280 nm (NanoDrop 2000c Spectrophotometer, ThermoScientific) and confirmed by Bradford assay. 
Assay of Ligand Binding to Ls-AChBP.
A scintillation proximity assay was employed to measure ligand binding to AChBP using [ 3 H]-epibatidine (5 nM, GE Healthcare) as the labeled ligand, polyvinyltoluene anti-mouse SPA scintillation beads (0.17 mg/mL final concentration, GE Healthcare), monoclonal anti-FLAG M2 antibody from mouse 1:8000 dilution (Sigma), and 0.50 nM AChBP in binding sites (2) . Initial screens required dissociation of 50% of the bound epibatidine by 10 µM of the candidate competitive ligand. Full concentration curves were then generated for these higher affinity ligands. Nonspecific binding was determined in parallel by adding a saturating concentration (12.5 μM) of MLA (Tocris). The resulting mixtures were allowed to equilibrate at room temperature for a minimum of 1 h and measured on a 1450 MicroBeta TriLux liquid scintillation counter (Wallac). Dissociation constants and Hill coefficients were determined from the competition profiles, concentration of epibatidine and its K d (0.30 nM) (GraphPad Prism 6). All measurements were completed in triplicate. Nicotine dissociation of labeled epibatidine was employed as a frame of reference.
Crystallography.
Complex Formation and Crystallization.
Complexes of multiple substituted 2-aminopyrimidines were prepared for crystallization as described (2) . Ligand -Ls-AChBP complexes was formed by combining 2 μL of a solution of a compound (10 mM dissolved in DMSO) with 48 μL of the protein at a concentration of 5 mg/mL to achieve a stoichiometric excess of ligand to binding sites. Cocrystals were obtained by the vapor diffusion hanging drop method. 
Data Collection, Phasing, and Model Refinement.
A full set of X-ray diffraction data was collected at 100 K at the Advanced Light Source Synchrotron in Berkeley, California (BL 8.2.2). Data were processed using the HKL2000 program. Ligand -Ls-AChBP complex structures were solved by molecular replacement method with Phaser-MR using an ensemble of AChBP structures (PDB entry 1UX2) as the search model. The electron density maps were fitted with COOT, and structure refinement used the program Phenix-1.8.4. Refinement statistics are listed in Table S2 . Atomic coordinates and structure factors of the complex have been deposited in the Protein Data Bank (PDB entries 4QAA, 4QAB and 4QAC). The structural figures were generated using PyMOL. 
Refinement Statistics.
Crystallographic data analysis.
All calculations were performed with Sigma Plot using X-ray crystal structure coordinates for Cα atoms of 1 pentamer (Ls-AChBP: residues 0-204). For Ls-AChBP crystal structures, its Apo form (PDB code: 1UX2) was used as a reference. For GLIC, crystal structure obtained at pH 4 (PDB code: 4NPP) was used as a reference. For residues 233-253 alternative conformation 'B' was used for calculations. Figure S2 . Comparison of Ls-AChBP quaternary changes with changes observed for GLIC; (A) Overlay of LsAChBP crystal structure in its Apo form (PDB code: 1UX2, shown in blue) and in complex with ligand 15 (in red), with GLIC X-ray crystal structure at pH 7.5 (PDB code: 4NPQ, shown in grey); X-ray structure of LsAChBP complex with nicotine and carbamylcholine (carbachol) used as controls (PDB codes: 1UW6 and 1UV6 respectively); stars represents position of the reference residues on protein axis; (B) Chart representing 'bloom'; x axis: delta distance between C α observed in Ls-AChBP -ligand complexes when compared with Ls-AChBP Apo form (GLIC: X-ray structure obtained at pH 7.5 compared to the structure at pH 4); y axis: relative distance from the protein vestibule. (C) Chart representing 'twist' of the pentameric structure; x axis: delta dihedral angle between C α observed in Ls-AChBP -ligand complexes when compared with Ls-AChBP Apo form (GLIC: X-ray structure obtained at pH 7.5 compared to the structure at pH 4); y axis: relative distance from the reference residue.
19 Figure S3 . Comparison of delta distance  SD ('bloom') observed in the Ls-AChBP complexes binding pocket; nicotine X-ray structure used as a control. Since in Ls-AChBP complex with ligand 15 some residues in C-loop had no defined densities in four chains of the pentamer, values for residues 185, 187 and 188 could not be generated. (Fig. S2, Panels B and C) . Structure alignment (UCSF Chimera) of Ls-AChBP with GLIC X-ray crystal structures superimposed terminal residue 205 of Ls-AChBP complex with residue 194 of GLIC, which is located in the protein vestibule region. Projections of residues position (obtained by averaging coordinates from all five chains for every residue; whenever a residue was missing in one or more chains in a pentamer, it was omitted in this analysis) taper toward an axis passing through the center of the pentagon. Relative distances from the vestibule were obtained by calculating distances between points defined by average of five coordinates for every residue and a point defined by average coordinates for the reference residue (residue 205 for Ls-AChBP and residue 194 for GLIC).
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